Hypophosphatemia (Low Blood Phosphate)

Hypophosphatemia means the level of phosphate in the blood is lower than normal. Phosphate is a mineral the body needs for strong bones, muscle function, and energy production. Mild cases may cause no symptoms. More severe or prolonged cases can cause fatigue, muscle weakness, bone pain, and softening of the bones (osteomalacia) that can lead to fractures.

The condition is at the center of litigation over Injectafer (ferric carboxymaltose), an intravenous iron treatment for iron deficiency anemia. On September 1, 2026, the FDA announced it had added a boxed warning, its most prominent safety warning, to Injectafer's labeling to describe the risk of symptomatic hypophosphatemia. The agency said reports continued to come in despite earlier label changes in February 2020 and May 2023 that added and strengthened the warning. According to the FDA, consequences in reported cases included hospitalization and phosphate replacement therapy lasting weeks to months.

Lawsuits allege that the drug's makers knew about the phosphate risk well before the label warned doctors and patients adequately, and that some patients suffered lasting bone and muscle problems as a result. These are individual injury claims, not a class action. A person considering a claim would typically need records showing the Injectafer infusions, blood tests showing low phosphate afterward, and treatment for symptoms.

Timing matters because every state sets a filing deadline for injury claims. Our guide to class actions versus mass torts explains how drug injury cases work, how to sue a company covers the basic steps, and a free case review can help you learn whether your situation fits current cases.